250 related articles for article (PubMed ID: 35980188)
1. Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.
Vásquez-Ponce F; Dantas K; Becerra J; Melocco G; Esposito F; Cardoso B; Rodrigues L; Lima K; de Lima AV; Sellera FP; Mattos R; Trevisoli L; Vianello MA; Sincero T; Di Conza J; Vespero E; Gutkind G; Sampaio J; Lincopan N
Microbiol Spectr; 2022 Oct; 10(5):e0115922. PubMed ID: 35980188
[TBL] [Abstract][Full Text] [Related]
2. A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex.
Lima KO; de Lima AV; Rocha DADC; Sampaio SCF; Cappellano P; Sampaio JLM
J Glob Antimicrob Resist; 2022 Mar; 28():49-52. PubMed ID: 34936924
[TBL] [Abstract][Full Text] [Related]
3. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
[TBL] [Abstract][Full Text] [Related]
4. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
5. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
7. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of a Stable and Transferable
Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
10. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
[TBL] [Abstract][Full Text] [Related]
11. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
12. Emergence of ceftazidime-avibactam resistance in bla
Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
[TBL] [Abstract][Full Text] [Related]
13. Increased Expression and Amplification of
Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
[TBL] [Abstract][Full Text] [Related]
14. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
[TBL] [Abstract][Full Text] [Related]
15.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms Driving the
Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
[TBL] [Abstract][Full Text] [Related]
17. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
18. KPC-2 allelic variants in
Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-Avibactam Resistance Associated with Increased
Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
